<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04756375</url>
  </required_header>
  <id_info>
    <org_study_id>APHP190729</org_study_id>
    <secondary_id>IDRCB2020-A00599-30</secondary_id>
    <nct_id>NCT04756375</nct_id>
  </id_info>
  <brief_title>Evaluation of Virtual Reality to Save Morphinic in the Treatment of Vaso-occlusive Seizures of Sickle Cell Patients Consulting in the Emergency Room</brief_title>
  <acronym>ReVCVO</acronym>
  <official_title>Evaluation of Virtual Reality to Save Morphinic in the Treatment of Vaso-occlusive Seizures of Sickle Cell Patients Consulting in the Emergency Room</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The management of pain in the emergency department is a major issue, especially for sickle&#xD;
      cell patients who regularly consult for vaso-occlusive seizure (VOS). The place of virtual&#xD;
      reality remains to be defined in a busy environment, in which the permanence of care&#xD;
      generates a significant turn over of medical and paramedical personnel.&#xD;
&#xD;
      With Its immersive nature, allowing the patient to detach from his immediate environment,&#xD;
      wich is often stressful for patients, we can hope that in multimodal management, Virtual&#xD;
      Reality (VR) can contribute to a faster reduction in pain with lower doses of morphine, but&#xD;
      so far we have no data.&#xD;
&#xD;
      Our pilot study aims to assess the effectiveness, feasibility and tolerance of adding virtual&#xD;
      reality to the management of VOS in sickle cell patients in the ER.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It will be a Before-after study: this study will be conducted in 2 phases in the emergency&#xD;
      department&#xD;
&#xD;
        -  a period of usual management of sickle cell patients with VOS&#xD;
&#xD;
        -  then a phase during which the device will be used. Each phase will last 3 months; the&#xD;
           duration of the periods may be shorter if recruitment targets are met. Patients will be&#xD;
           included consecutively.&#xD;
&#xD;
      The main objective of the study is to measure the impact of virtual reality on the total dose&#xD;
      of morphine administered to the emergency room in the treatment of vaso-occlusive seizures&#xD;
      after initial morphine titration.&#xD;
&#xD;
      The primary endpoint is the total dose of morphine (in milligrams), used in the emergency&#xD;
      room after initial titration, meaning the dose administered by PCA (patient-controlled&#xD;
      analgesia) and secondary titrations in the event of a recurrence of painful spikes with&#xD;
      analog verbal scale (AVS) &gt;7.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 4, 2021</start_date>
  <completion_date type="Actual">September 2, 2021</completion_date>
  <primary_completion_date type="Actual">September 2, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total dose of morphine</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>Total dose of morphine (in milligrams), used in the emergency room after initial titration, meaning the dose administered by PCA and secondary titrations in case of recurrence of painful peak with AVS&gt;7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of implementing the scheme</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>Number of patents included in the protocol vs. number of potentially eligible patients For patients included during the VR period: the number of VR sessions performed, and the duration of these sessions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>Side effects such as headache, nausea, eye pain or dizziness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>Patient's willingness to use VR again at future VOS Evaluation of patient satisfaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Efficiency</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>Evaluation of AVS before and after the virtual reality session Numbers of painful areas before and after virtual reality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Vaso-occlusive Crisis</condition>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>INTERVENTION</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of virtual reality in the management of sickle cell patients with VOS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NO INTERVENTION</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Virtual Reality</intervention_name>
    <description>Use of virtual reality in the management of sickle cell patients with VOS</description>
    <arm_group_label>INTERVENTION</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Usual management of sickle cell patients with VOS</description>
    <arm_group_label>NO INTERVENTION</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  sickle cell patient consulting in the emergency room for VOS&#xD;
&#xD;
          -  Signature free and informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Consultation in the ER for the same reason in the 14 days prior to inclusion (same&#xD;
             episode)&#xD;
&#xD;
          -  Emergency room consultation more than 12 times in the previous year&#xD;
&#xD;
          -  Nausea and vomiting at the time of inclusion&#xD;
&#xD;
          -  History of epilepsy&#xD;
&#xD;
          -  A visually impaired or hard of hearing patient&#xD;
&#xD;
          -  Pregnant patient&#xD;
&#xD;
          -  Previous inclusion in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélène GOULET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HOPITAL TENON Service des urgences</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Virtual reality</keyword>
  <keyword>Vaso occlusive seizure</keyword>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Emergency Room</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

